THC for Type 2 Diabetes
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, you must have a stable medication regimen for at least 3 months before joining the study.
What evidence supports the effectiveness of the drug THC for Type 2 Diabetes?
Research suggests that THC, a component of marijuana, may influence insulin secretion and glucose metabolism, which are important for managing diabetes. Studies in animals have shown that activating certain cannabinoid receptors can improve glucose tolerance, indicating potential benefits for diabetes management.12345
Is THC safe for humans, especially those with type 2 diabetes?
There is limited safety data on THC specifically for type 2 diabetes, but related studies suggest that cannabis use can affect metabolic regulation and may alter treatment adherence in diabetes patients. Additionally, rimonabant, a drug targeting the same system as THC, was generally well-tolerated but had some side effects like mood disorders and nausea.26789
How does the drug THC differ from other treatments for type 2 diabetes?
THC (Tetrahydrocannabinol) is unique because it interacts with the endocannabinoid system, which is involved in regulating metabolism and energy balance, potentially affecting insulin secretion and glucose levels. Unlike standard diabetes treatments, THC may also influence immune responses and has been shown to modify insulin secretion in experimental models, offering a novel approach to managing diabetes-related metabolic changes.59101112
What is the purpose of this trial?
This study will examine the effects THC has on Glucose Metabolism and Endothelial Functioning in participants with Type 2 Diabetes. The participants will complete blood tests and tests to measure energy expenditure, CVD risks, and glucose metabolism. These tests will be performed prior to start of treatment and again after 2-weeks of treatment with the THC or placebo.
Eligibility Criteria
Adults aged 21-70 with Type 2 Diabetes, a BMI over 25 kg/m2, and stable diabetes medication for at least 3 months can join. They must not use tobacco or THC products recently, have no significant illnesses or heart issues, and agree to contraception if of childbearing potential.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment Session 1
Participants receive either THC or placebo for 2 weeks with metabolic and endothelial assessments
Washout
Participants undergo a 4-week washout period before switching treatments
Treatment Session 2
Participants receive the opposite treatment (THC or placebo) for 2 weeks with metabolic and endothelial assessments
Safety Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Placebo
- THC
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Diego
Lead Sponsor
Center for Medicinal Cannabis Research
Collaborator
Center For Medicinal Cannabis Research at UC San Diego Health
Collaborator